USANA Health Sciences, Inc. (USNA) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Nature's Sunshine Products, Inc.

Chromadex Corp.

USANA Health Sciences, Inc.

ProPhase Labs, Inc.

LifeVantage Corp.

Natural Alternatives International, Inc.

Upexi, Inc.

Revolution Medicines, Inc.

Cidara Therapeutics, Inc.

MIRA Pharmaceuticals, Inc.

Bright Green Corp.

Why is USANA Health Sciences, Inc. ?

The company has declared negative results for the last 7 consecutive quarters

INTEREST(HY) At USD 0.67 MM has Grown at 550.49%
OPERATING CASH FLOW(Y) Lowest at USD 63.01 MM
NET PROFIT(HY) At USD 19.06 MM has Grown at -29.34%

With ROE of 6.57%, it has a attractive valuation with a 1.03 Price to Book Value

The stock is trading at a premium compared to its peers' average historical valuations
Over the past year, while the stock has generated a return of -45.71%, its profits have fallen by -43.8%

Consistent Underperformance against the benchmark over the last 3 years

Along with generating -45.71% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is USANA Health Sciences, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

USANA Health Sciences, Inc.

-37.98%

-1.18

47.62%

S&P 500

25.41%

0.70

20.15%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-4.00%

EBIT Growth (5y)

-22.03%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.30

Sales to Capital Employed (avg)

1.70

Tax Ratio

47.24%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

63.93%

ROCE (avg)

70.81%

ROE (avg)

18.61%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

0.59

EV to EBIT

3.41

EV to EBITDA

1.92

EV to Capital Employed

0.44

EV to Sales

0.19

PEG Ratio

Dividend Yield

ROCE (Latest)

12.90%

ROE (Latest)

4.67%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

No Trend

Mildly Bearish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

5What is working for the Company

NET PROFIT(Q)

At USD 7.51 MM has Grown at 433.76%

DEBTORS TURNOVER RATIO(HY)

Highest at 191.76 times

NET SALES(Q)

Highest at USD 250.22 MM

-15What is not working for the Company

NET PROFIT(HY)

At USD 0.61 MM has Grown at -95.59%

OPERATING CASH FLOW(Y)

Lowest at USD 16.63 MM

ROCE(HY)

Lowest at 1.65%

CASH AND EQV(HY)

Lowest at USD 321.13 MM

DEBT-EQUITY RATIO (HY)

Highest at -27.37 %

Here's what is working for USANA Health Sciences, Inc.

Net Profit

At USD 7.51 MM has Grown at 433.76%

over average net sales of the previous four periods of USD 1.41 MM

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (USD MM)

Net Sales

Highest at USD 250.22 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (USD MM)

Debtors Turnover Ratio

Highest at 191.76 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Here's what is not working for USANA Health Sciences, Inc.

Operating Cash Flow

Lowest at USD 16.63 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Cash and Eqv

Lowest at USD 321.13 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debt-Equity Ratio

Highest at -27.37 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio